Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Boston Scientific (BSX) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Boston Scientific is one of 1009 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for BSX's full-year earnings has moved 4.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.Our latest available data shows that BSX has returned about 17% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 5.7% on average. As we can see, Boston Scientific is performing better than its sector in the calendar year.Another stock in the Medical sector, Abivax SA Sponsored ADR (ABVX), has outperformed the sector so far this year. The stock's year-to-date return is 10.4%.For Abivax SA Sponsored ADR, the consensus EPS estimate for the current year has increased 10.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Looking more specifically, Boston Scientific belongs to the Medical - Products industry, a group that includes 83 individual stocks and currently sits at #83 in the Zacks Industry Rank. On average, this group has gained an average of 10.4% so far this year, meaning that BSX is performing better in terms of year-to-date returns.On the other hand, Abivax SA Sponsored ADR belongs to the Medical - Biomedical and Genetics industry. This 510-stock industry is currently ranked #64. The industry has moved +6.8% year to date.Going forward, investors interested in Medical stocks should continue to pay close attention to Boston Scientific and Abivax SA Sponsored ADR as they could maintain their solid performance.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Abivax SA Sponsored ADR (ABVX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks